CRWD
CrowdStrike Holdings, Inc.
CRWD has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CRWD overall, supported by stronger valuation and stronger fundamentals.
CRWD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Strong | |
| Unavailable |
CRWD's revenue and cash flow are currently healthy, and its profitability is stable. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRWD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 153x | $230 | — |
| Cheap | 451x | $27.04 | -88% |
| Fair | 715x | $42.92 | -81% |
| Expensive | 3,337x | $200 | -13% |
| Current | 3,678x | $230 | — |
Historical ranges are pointers, not guarantees.
CRWD's PE is in its expensive range at 3678x. If earnings grow as analysts expect, today's price would be 153x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CRWD in the historical PE scenario, which offers more potential upside but is not a forecast.
CRWD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Broad | |
| High |
Analysts expect strong earnings and revenue growth for CRWD, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CRWD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.50 | +2400% |
| Q3 2026 | $0.06 | +$0.36 |
| Q2 2026 | -$0.03 | +$0.14 |
| Q1 2026 | -$0.16 | -$0.14 |
| Q4 2025 | -$0.32 | -346% |
| Q3 2025 | -$0.30 | -276% |
| Q2 2025 | -$0.17 | -221% |
| Q1 2025 | -$0.02 | -122% |
| Q4 2024 | $0.13 | +$0.15 |
CRWD has returned to profit: it earned $0.06 per share over the past year, after losing money the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CRWD on earnings, with more consistent year-over-year improvement.
CRWD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +26% |
| Q2 2026 | $1.4B | +26% |
| Q1 2026 | $1.3B | +23% |
| Q4 2025 | $1.2B | +22% |
| Q3 2025 | $1.2B | +21% |
| Q2 2025 | $1.1B | +20% |
| Q1 2025 | $1.1B | +25% |
| Q4 2024 | $1B | +29% |
CRWD's revenue has grown year over year every quarter since late 2020: $1.5B last quarter, up 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.3% | +7.4 points |
| Q2 2026 | -2.2% | +9.1 points |
| Q1 2026 | 1.1% | +9.1 points |
| Q4 2025 | -5.6% | -0.1 points |
| Q3 2025 | -9.7% | -11 points |
| Q2 2025 | -11% | -12 points |
| Q1 2025 | -8.1% | -12 points |
| Q4 2024 | -5.5% | -5.9 points |
CRWD's operating margin was −2.3% last quarter, up 7.4 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CRWD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CRWD on profitability, with a higher operating margin.
CRWD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $405.9M | +34% |
| Q2 2026 | $493.3M | +65% |
| Q1 2026 | $395.4M | +53% |
| Q4 2025 | $314.1M | +27% |
| Q3 2025 | $302.3M | +5.2% |
| Q2 2025 | $298.4M | -11% |
| Q1 2025 | $258.5M | -12% |
| Q4 2024 | $247.4M | -1.9% |
CRWD's free cash flow has been positive every quarter for seven years: $1.6B over the past year, up 45% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CRWD on cash flow, with more consistent year-over-year improvement.
CRWD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +12.9M shares |
| 1 year | +4.5% | +44.8M shares |
| 3 years | +7.8% | +75.9M shares |
| 5 years | +15% | +139M shares |
| Available history | +28% | +228M shares |
CRWD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $175.6M |
| Q1 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CRWD Net Leverage
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CRWD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.1 | Neutral |
| Stochastic | 49.1 | Neutral |
CRWD's weekly RSI is 55 (neutral) and its Stochastic is 49 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CRWD PE vs Technology Sector
| Metric | CRWD | Sector median | Relative |
|---|---|---|---|
| PE | 3,678x | 28x | 13,101% above |
| PE % | 91 | 35 | 56 pts above |
CRWD is trading at 3678x earnings, a 13101% premium to the Technology sector's median of 28x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over CRWD on valuation relative to its sector.
CRWD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $247.4 | 7.1% below |
| 20 week MA | $221.9 | 3.6% above |
| 50 week MA | $163.0 | 41% above |
| 100 week MA | $136.0 | 69% above |
| 200 week MA | $97.5 | 136% above |
CRWD's trend is up, with a small recent dip: it's below only its 8-week average, and 136% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CRWD on trend strength, trading above more of its moving averages.
CRWD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.2 | $55.3 | +352% |
| 2021 | $55.3 | $52.9 | -4.3% |
| 2022 | $52.9 | $25.5 | -52% |
| 2023 | $25.5 | $63.8 | +150% |
| 2024 | $63.8 | $88.8 | +39% |
| 2025 | $88.8 | $120.3 | +36% |
| 2026 YTD | $120.3 | $229.9 | +91% |
CRWD's yearly returns have swung widely, from +352% in 2020 to −52% in 2022. It's up 91% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CRWD on returns for 2026, with the stronger performance.